Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Study to Evaluate the Anti-Tumor Activity of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03739606
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:54.188998+00:00
Published At
2020-12-17T00:00:00+00:00
Record Updated At
2020-12-17
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Acute Biphenotypic Leukemia", "Acute Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Hairy Cell Leukemia", "Interleukin-3 Receptor Subunit Alpha Positive", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Recurrent Hematologic Malignancy", "Recurrent Hodgkin Lymphoma", "Refractory Acute Lymphoblastic Leukemia", "Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm", "Refractory Hematologic Malignancy", "Refractory Hodgkin Lymphoma", "Systemic Mastocytosis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2020-12-17"
protocolSection.identificationModule.nctId
"NCT03739606"
protocolSection.identificationModule.officialTitle
"A Phase 2 Study to Evaluate the Anti-Tumor Activity of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies"
protocolSection.statusModule.overallStatus
"WITHDRAWN"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Acute Biphenotypic Leukemia (protocolSection.conditionsModule.conditions)
  • Acute Leukemia (protocolSection.conditionsModule.conditions)
  • Chronic Myelogenous Leukemia, BCR-ABL1 Positive (protocolSection.conditionsModule.conditions)
  • Hairy Cell Leukemia (protocolSection.conditionsModule.conditions)
  • Interleukin-3 Receptor Subunit Alpha Positive (protocolSection.conditionsModule.conditions)
  • Recurrent Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm (protocolSection.conditionsModule.conditions)
  • Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive (protocolSection.conditionsModule.conditions)
  • Recurrent Hematologic Malignancy (protocolSection.conditionsModule.conditions)
  • Recurrent Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (protocolSection.conditionsModule.conditions)
  • Refractory Hematologic Malignancy (protocolSection.conditionsModule.conditions)
  • Refractory Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Systemic Mastocytosis (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.